MEDIAN Technologies is developing next generation medical imaging technology dedicated to oncology clinical trials, cancer screening, and clinical practice. The technology enables pharmaceutical customers and clinicians to accurately measure 3D changes in tumour morphology, including density gradients, to optimise the diagnosis of cancer patients and the assessment of their response to therapy. The company's iBiopsy is a next generation non-invasive cancer screening and monitoring tool that should significantly improve the detection, diagnosis and monitoring of disease. MEDIAN is a VIPE (Venture Investment in Public Equity) and is listed on Euronext.